Novartis leads and Bristol lags on novel drug approvals
Big pharma delivered 76 novel medicines to the market over the past five years, but some companies contributed more than others.
The big approvals still on the cards for 2021
Biogen’s Aduhelm was the big one, but there are plenty of other key regulatory decisions still pending this year.
Biogen and the social contract
The pricing of Aduhelm has been compared to that of Sovaldi, but this ignores the fact that Sovaldi actually worked.
Biogen makes history with Alzheimer’s approval
A green light from the US regulator for aducanumab is a huge boost for Biogen, but not everyone will be celebrating.
